Filed Under NEWS FROM AROUND THE WEB
FDA Poised to Review Two New Drugs for Type 2 Diabetes
The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.


Add a Comment